RxDoctor Payments Data

Edwin Diaz, MD

Urology · North Little Rock, ARNPI 1275508939

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $111,000 of the $125,456 with a category attached, or 88.5%. Cryo Specialty Medical, LLC accounts for 99.2% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $38,147 and has fallen 99.5% since, to $184 in 2025. Among urology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$125,456in general payments, 2019–2025

Across 47 payments — averaging $2669.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cryo Specialty Medical, LLC$125K
  • Procept Biorobotics Corporation$236
  • Teleflex LLC$169
  • AbbVie$112
  • Axonics, Inc.$72
  • Amgen$66
  • plus $302 from 11 others

What the payments were for

  • Speaking & faculty fees$13,50011%
  • Food & beverage$9561%
  • Ownership interest$111,00088%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$125,456 in reported general payments places this provider in the 90th percentile of 88 urology providers in Arkansas.

See all urology providers in Arkansas

Medicare billing

Part B allowed, 2024
$644,821
Medicare patients
1,245
Services billed
11,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron141$95,034
Tamsulosin Hcl656$8,234
Oxybutynin Chloride ErOxybutynin Chloride518$7,912
Solifenacin Succinate121$6,220
GemtesaVibegron11$6,187
Finasteride325$3,669
Tolterodine Tartrate ErTolterodine Tartrate23$2,305
Fesoterodine Fumarate ErFesoterodine Fumarate19$1,382
Dutasteride17$774
Oxybutynin Chloride40$645
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst42$591
Potassium Citrate ErPotassium Citrate13$497
Cephalexin114$487
Ciprofloxacin Hcl91$440
Levofloxacin123$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$14$6,18711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 88 urology providers in Arkansas.

Other urology in North Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →